Mayne Pharma Group Limited (MYX.AX)

AUD 4.85

(-2.02%)

Net Debt Summary of Mayne Pharma Group Limited

Mayne Pharma Group Limited's latest annual net debt in 2024 was -78.42 Million AUD , down -31.43% from previous year.
Mayne Pharma Group Limited's latest quarterly net debt in 2024 FY was -73.56 Million AUD , down -35.71% from previous quarter.
Mayne Pharma Group Limited reported annual net debt of -54.2 Million AUD in 2023, down -117.12% from previous year.
Mayne Pharma Group Limited reported annual net debt of 316.58 Million AUD in 2022, up 27.42% from previous year.
Mayne Pharma Group Limited reported quarterly net debt of -73.56 Million AUD for 2024 FY, down -35.71% from previous quarter.
Mayne Pharma Group Limited reported quarterly net debt of -78.42 Million AUD for 2024 Q4, down 0.0% from previous quarter.

Annual Net Debt Chart of Mayne Pharma Group Limited (2024 - 2007)

Historical Annual Net Debt of Mayne Pharma Group Limited (2024 - 2007)

Year	Net Debt	Net Debt Growth
2024	-78.42 Million AUD	-31.43%
2023	-54.2 Million AUD	-117.12%
2022	316.58 Million AUD	27.42%
2021	248.46 Million AUD	-4.38%
2020	259.85 Million AUD	-7.32%
2019	280.37 Million AUD	-2.27%
2018	286.87 Million AUD	3.48%
2017	277.21 Million AUD	844.43%
2016	29.35 Million AUD	1048.85%
2015	2.55 Million AUD	-92.31%
2014	33.21 Million AUD	19.66%
2013	27.76 Million AUD	339.39%
2012	-11.59 Million AUD	-234.37%
2011	-3.46 Million AUD	68.74%
2010	-11.09 Million AUD	-39.83%
2009	-7.93 Million AUD	31.16%
2008	-11.52 Million AUD	24.65%
2007	-15.29 Million AUD	0.0%

Year	Net Debt	Net Debt Growth
2024 Q2	-72.65 Million AUD	0.0%
2024 FY	-73.56 Million AUD	-35.71%
2024 Q4	-78.42 Million AUD	0.0%
2023 FY	-54.2 Million AUD	-117.12%
2023 Q4	-54.2 Million AUD	0.0%
2023 Q2	-94.3 Million AUD	0.0%
2022 Q2	272.53 Million AUD	0.0%
2022 Q4	316.58 Million AUD	0.0%
2022 FY	316.58 Million AUD	27.42%
2021 Q2	220.57 Million AUD	0.0%
2021 Q4	248.46 Million AUD	0.0%
2021 FY	248.46 Million AUD	-4.38%
2020 FY	259.85 Million AUD	-7.32%
2020 Q4	259.85 Million AUD	0.0%
2020 Q2	290.16 Million AUD	0.0%
2019 Q2	298.4 Million AUD	0.0%
2019 FY	280.37 Million AUD	-2.27%
2019 Q4	280.37 Million AUD	0.0%
2018 Q2	303.13 Million AUD	0.0%
2018 Q4	286.87 Million AUD	0.0%
2018 FY	286.87 Million AUD	3.48%
2017 Q2	232.25 Million AUD	0.0%
2017 FY	277.21 Million AUD	844.43%
2017 Q4	277.21 Million AUD	0.0%
2016 Q4	30.18 Million AUD	0.0%
2016 FY	29.35 Million AUD	1048.85%
2016 Q2	15.06 Million AUD	0.0%
2015 FY	2.55 Million AUD	-92.31%
2015 Q2	39.73 Million AUD	0.0%
2015 Q4	2.55 Million AUD	0.0%
2014 Q2	35.72 Million AUD	0.0%
2014 Q4	33.21 Million AUD	0.0%
2014 FY	33.21 Million AUD	19.66%
2013 Q4	27.76 Million AUD	246.58%
2013 Q2	-30.38 Million AUD	0.0%
2013 FY	27.76 Million AUD	339.39%
2013 Q3	-18.93 Million AUD	37.66%
2012 FY	-11.59 Million AUD	-234.37%
2012 Q4	-11.59 Million AUD	0.0%
2011 Q4	-3.46 Million AUD	0.0%
2011 FY	-3.46 Million AUD	68.74%
2010 Q4	-11.09 Million AUD	0.0%
2010 FY	-11.09 Million AUD	-39.83%
2009 Q4	-7.93 Million AUD	0.0%
2009 FY	-7.93 Million AUD	31.16%
2008 FY	-11.52 Million AUD	24.65%
2008 Q4	-11.52 Million AUD	0.0%
2007 Q4	-15.29 Million AUD	0.0%
2007 FY	-15.29 Million AUD	0.0%

Peer Net Debt Comparison of Mayne Pharma Group Limited

Name	Net Debt	Net Debt Difference
Firebrick Pharma Limited	-824.77 Thousand AUD	-9408.885%